AMPA statement – Covid19
March 20, 2020
After careful monitoring of the rapidly changing situation related to COVID-19, understanding that concerns for health, safety, and the impact on meeting attendance, among other issues, are affecting our conference, the difficult decision has been made to cancel CCTMC for 2020. We are committed to maintaining appropriate health and safety measures, and we encourage you to follow guidelines recommended by the Centers for Disease Control and Prevention and the World Health Organization. CCTMC attendees and exhibitors will be issued a full refund or may choose to roll their registration to the 2021 conference. Watch our websites, Facebook and www.CCTMC.net for details for 2021 as they become available in the near future. You won’t want to miss it!Best regards,AMPA, ASTNA, IAFCCP
AMPA Position Statement
AMPA is attentive to the concerns of its membership in addressing the challenges associated with the transport of patients with suspected or confirmed infection with SARS-CoV-2. Recommendations regarding the personal protective equipment required to care for these patients remain fluid, and AMPA recommends that its members remain familiar with the recommendations of the World Health Organization as well as those of their local, regional, and national health protection authorities.
• AMPA supports social distancing and recommends seeking alternatives to gatherings of greater than ten people.
• AMPA supports the WHO recommendation to employ standard, contact, and droplet precautions when caring for and transporting patients with suspected or confirmed infection with SARS-CoV-2.
⁃ AMPA recommends that patients with suspected or confirmed infection with SARS-CoV2 wear a surgical mask during care and transport.
• AMPA supports the WHO recommendation to employ standard, contact, and airborne precautions when caring for and transporting patients with suspected or confirmed infection with SARS-CoV-2 who are undergoing aerosol-generating procedures such as nebulization, mask oxygenation, high flow nasal cannula oxygenation, non-invasive positive pressure ventilation, endotracheal intubation, bag valve mask ventilation, cricothyrotomy, tracheostomy, and cardiopulmonary resuscitation.
⁃ AMPA further supports the WHO recommendation to attempt to avoid performing aerosol-generating procedures in confined spaces.
⁃ AMPA therefore cautions against transporting patients anticipated to require aerosolgenerating procedures during transport and suggests mitigating the need for aerosolgenerating procedures prior to transport.
⁃ AMPA recommends the use of a certified bacterial and viral filter in the ventilator circuit of mechanically ventilated patients but recommends airborne precautions during transport to safeguard against unanticipated aerosol-generating procedures.
⁃ AMPA further recommends the mitigating use of a certified bacterial and viral filter (1) between the bag and the endotracheal tube or between the bag and the face mask of manually ventilated patients, and (2) in the circuit of patients being provided noninvasive positive pressure ventilation, when feasible.
⁃ AMPA further acknowledges that local, regional, or national practice may be to employ airborne precautions on a broader population of patients with suspected or confirmed infection with SARS-CoV-2 and that these recommendations remain fluid.
• AMPA recommends that pilots and other vehicle operators employ droplet or airborne precautions as appropriate, utilizing appropriately fit-tested personal protective equipment, unless the cockpit and patient compartment are completely separated.
• AMPA cautions that using a particulate respirator mask while wearing a flight helmet may render the mask ineffective unless appropriate fit testing has been performed while wearing the helmet.
• AMPA acknowledges that SARS-CoV-2 may survive in the environment for extended periods of time and recommends decontamination of all surfaces and open air ventilation of the patient compartment following the transport of patients with suspected or confirmed infection with SARS-CoV-2.
AMPA acknowledges that our understanding of potential best practices remains fluid at this time and recommends careful consideration of current guidelines and continuous reassessment of the potential benefits and risks surrounding the transport of patients with suspected or confirmed infection with SARS-CoV-2. AMPA will continuously review these recommendations and provide interim guidance as necessary.